JAMP DIMETHYL FUMARATE CAPSULE (DELAYED RELEASE)

Maa: Kanada

Kieli: englanti

Lähde: Health Canada

Aktiivinen ainesosa:

DIMETHYL FUMARATE

Saatavilla:

JAMP PHARMA CORPORATION

ATC-koodi:

L04AX07

INN (Kansainvälinen yleisnimi):

DIMETHYL FUMARATE

Annos:

120MG

Lääkemuoto:

CAPSULE (DELAYED RELEASE)

Koostumus:

DIMETHYL FUMARATE 120MG

Antoreitti:

ORAL

Kpl paketissa:

15G/50G

Prescription tyyppi:

Prescription

Terapeuttinen alue:

MISCELLANEOUS CENTRAL NERVOUS SYSTEM AGENTS

Tuoteyhteenveto:

Active ingredient group (AIG) number: 0154210001; AHFS:

Valtuutuksen tilan:

APPROVED

Valtuutus päivämäärä:

2021-10-04

Valmisteyhteenveto

Pr
JAMP DIMETHYL FUMARATE
_ _
_(dimethyl fumarate delayed-release capsules)_ Page 1 of 43
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
JAMP DIMETHYL FUMARATE
Dimethyl fumarate delayed-release capsules
Delayed-release capsules, 120 mg and 240 mg, oral
Antineoplastic and Immunomodulating Agents
JAMP Pharma Corporation
1310 rue Nobel
Boucherville, Quebec
J4B 5H3, Canada
Date of Initial Authorization:
October 04, 2021
Date of Revision:
January 9, 2024
Submission Control Number: 277583
Pr
JAMP DIMETHYL FUMARATE
_ _
_(dimethyl fumarate delayed-release capsules)_ Page 2 of 43
RECENT MAJOR LABEL CHANGES
7 WARNINGS AND PRECAUTIONS
01/2024
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
...........................................................................................
2
TABLE OF CONTENTS
.............................................................................................................
2
PART I: HEALTH PROFESSIONAL
INFORMATION.....................................................................
4
1
INDICATIONS
..............................................................................................................
4
1.1
Pediatrics
..............................................................................................................
4
1.2
Geriatrics
..............................................................................................................
4
2
CONTRAINDICATIONS
................................................................................................
4
4
DOSAGE AND ADMINISTRATION
................................................................................
4
4.1
Dosing Considerations
..........................................................................................
4
4.2
Recommended Dose and Dosage Adjustment
..................................................... 5
4.4
Administration
......................................................................